Analysis of Blood Transfusion Reactions in Pediatric Populations - Report - MDSpire

Analysis of Blood Transfusion Reactions in Pediatric Populations

  • By

  • Elizabeth F. Stone

  • Daniel Chacreton

  • Alexandra Jimenez

  • Shannon Kelly

  • Ruchika Goel

  • Jeanne E. Hendrickson

  • Marianne E. Nellis

  • Martha Sola-Visner

  • Oliver Karam

  • Ravi M. Patel

  • Sarah Vossoughi

  • Madhav Vissa

  • Sarah Wilson

  • Jeffrey J. VanWormer

  • Sylvia Titi Singer

  • Sara Bakhtary

  • Elliott P. Vichinsky

  • Naomi L.C. Luban

  • Cassandra D. Josephson

  • Matthew S. Karafin

  • NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P)

  • April 27, 2026

  • 0 min

Share

Clinical Report: Analysis of Blood Transfusion Reactions in Pediatric Populations

Overview

This multicenter study provides a comprehensive analysis of blood transfusion reactions in pediatric patients, revealing a higher incidence of febrile nonhemolytic transfusion reactions and allergic reactions compared to adults. The findings underscore the need for improved recognition, reporting practices, and targeted prevention strategies in pediatric transfusion safety.

Background

Blood transfusions are a common procedure in hospitalized patients, yet pediatric populations may experience higher rates of transfusion reactions. The lack of a standardized national hemovigilance system in the U.S. complicates the understanding of these reactions, making it essential to conduct robust analyses to inform clinical practices and guidelines. This study aims to fill existing knowledge gaps regarding pediatric transfusion reactions.

Data Highlights

{'incidence_rates': {'febrile_nonhemolytic': 'Specify incidence rate', 'allergic_reactions': 'Specify incidence rate'}}

Key Findings

{'demographic_features': 'List specific demographic and clinical features affecting reaction rates.'}

Clinical Implications

{'reporting_strategies': 'Provide examples of standardized reporting and prevention strategies.'}

Conclusion

{'future_research': 'Add a call to action for future studies.'}

References

  1. Intensive Care Medicine, 2008 -- Duration of Red Blood Cell Storage Does Not Influence Outcomes in Critically Ill Pediatric Patients
  2. Bone Marrow Transplantation, 2022 -- Acute Vascular Complications Following Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
  3. Bone Marrow Transplantation, 2020 -- Establishing and Maintaining Pediatric Blood and Marrow Transplant Services in Middle-Income Countries: Insights from the EBMT PDWP Experience
  4. NHSN Biovigilance Component Protocol -- CDC
  5. Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines | Bleeding and Transfusion | JAMA
  6. Bone Marrow Transplantation — Results of Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis in Pediatric Patients: A Retrospective Analysis from the EBMT Pediatric Diseases Working Party
  7. NHSN Hemovigilance Module
  8. Transfusion reactions in pediatric compared with adult patients
  9. Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines | Bleeding and Transfusion | JAMA | JAMA Network

Original Source(s)

Analysis of Blood Transfusion Reactions in Pediatric Populations

  • by Elizabeth F. Stone, Daniel Chacreton, Alexandra Jimenez, Shannon Kelly, Ruchika Goel, Jeanne E. Hendrickson, Marianne E. Nellis, Martha Sola-Visner, Oliver Karam, Ravi M. Patel, Sarah Vossoughi, Madhav Vissa, Sarah Wilson, Jeffrey J. VanWormer, Sylvia Titi Singer, Sara Bakhtary, Elliott P. Vichinsky, Naomi L.C. Luban, Cassandra D. Josephson, Matthew S. Karafin, NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P)

  • April 27, 2026

Related Content

Implementation and Evaluation of an Alternative Electronic Health Record Tool for Ordering Blood Products in Pediatric Oncology and Stem Cell Transplantation: Mixed Methods Analysis

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • by

  • May 7, 2026

  • 4 min